Charles (‘Chuck’) H. Munn, Jr.

About

Having spent the past several years back in private practice and most of his legal career as in-house counsel at international, privately held and publicly traded companies, Chuck brings a wealth of experience to Manning Fulton and its clients.

While in private practice with Manning Fulton, Chuck has focused on helping client in a wide array of corporate legal services including M&A, raising capital, SEC regulatory work, corporate debt financing, data privacy and protection, and other general corporate services.  Chuck is the head of the Life Sciences section for Manning Fulton and has a number of clients that he provides general counsel services in this space.

As a former in-house General Counsel and Assistant General Counsel, Chuck has been responsible for companies’ US and international legal operations and activities ensuring those companies conduct business in compliance with applicable global laws and regulations; led and negotiated US and international mergers, acquisitions, divestitures and joint ventures; transitioned private equity-controlled boards of directors and committees from private to publicly-owned status; managed companies’ compliance with regulations and filing requirements required by the Securities and Exchange Commission and NASDAQ; developed strategic plans for compliance with the European Union’s General Data Protection Regulation; and drafted and implemented business continuity, cash/equity compensation, and employee stock purchase plans.

In addition, Chuck has drafted and managed debt agreements and instruments ensuring companies comply with obligations and covenants under those debt facilities, including senior secured financing and publicly-traded notes; reviewed and finalized companies’ quarterly and annual financial statements ensuring proper financial disclosure under public filings; and managed companies’ overall risk management including the procurement and maintenance of international property and casualty and executive management liability insurance programs.

Chuck’s many years in both private practice and in-house legal departments provides him with a wide array of experience and a wealth of knowledge that he provides to Manning Fulton and its clients.

Credentials

Education

• Campbell University School of Law – J.D. – 1991 – Cum Laude
  • Campbell Law Review, Managing Editor
• Wake Forest University – B.S. in Accountancy – 1986 – Cum Laude

Admitted to Practice

• North Carolina – 1991
• Certified Public Accountant – North Carolina – 1988

Professional Activities

• North Carolina Bar Association – 1991 to Present
• North Carolina Association of Certified Public Accountants – 1988 to Present
• Recognized by Best Lawyers in America for Closely Held Companies and Family Businesses Law (2027)

Prior Experience:

• General Counsel, PRA Health Sciences, Inc., Raleigh, NC – 2016 – 2018
• Assistant General Counsel, Pharmaceutical Product Development, LLC, Wilmington, NC – 2003 – 2016
• General Counsel, Divi Hotels and Resorts, Chapel Hill, NC – 1996 – 2003
• Corporate Attorney, SAS Institute, Inc. – 1992 -1994
• Associate, Wyrick, Robbins, Yates & Ponton, LLP – 1991-92; 1994-96
• Tax Professional, Ernst & Young, LLP – 1986-88

Representative Transactions

PRA Health Sciences and Takeda Pharmaceutical Company Limited establish joint venture in Japann to provide clinical trial delivery and pharmacovigilance services

PRA Health Sciences equity acquisition of Parallel 6, Inc., a developer of technologies for improving patient enrollment, engagement, and management of clinical trials ($47.3 million)

PRA Health Sciences enters into a close strategic partnership with Takeda Pharmaceutical Company Limited whereby PRA becomes Takeda’s primary strategic partner for the clinical development and post-approval services for Takeda’s drug pipeline and marketed products.

PPD enters into strategic partnership ERT Clinical to facilitate ERT’s delivery of ts comprehensive patient safety and efficacy and endpoint data collection to assist with clinical trial efficiency

PPD enters into joint venture and collaboration with Shin Nippon Biomedical Laboratories for purposes of performing clinical development services in Japan

PPD acquires RCT Logic LLC’s exclusive clinical trial design license from Massachusetts General Hospital

PPD acquires remaining 40% equity interest of X-Chem, Inc., a company developing proprietary small molecule drug discovery services

PPD equity acquisition of Acruian, Inc., a patient recruitment firm operating in the US and Europe.

PPD formed BioDuro Biologics Pte Ltd., a Singapore joint venture to develop proprietary biological drug discovery services ($6.7 million)

PPD is acquired by private equity firms The Carlyle Group and Hellman and Freeman ($3.9 billion leveraged buyout)

PPD 60% equity acquisition of X-Chem, Inc., a company developing proprietary small molecule drug discovery services. Acquisition included time-based option to acquire remaining 40% ($15.5 million)

PPD spins off drug development segment into newly formed publicly-traded company, Furiex Pharmaceuticals, Inc. ($100 million)

PPD disposition of all equity ownership in wholly-owned subsidiary, PPD Biomarker Discovery Sciences, LLC, a PPD company that provided biomarker discovery services and participant sample analysis ($0.1 million plus percentage of future revenue)

PPD equity acquisition of Excel PharmaStudies, Inc., a contract research organization operating in China ($22.2 million)

PPD equity acquisition of BioDuro, LLC, a drug discovery services company operating China ($78.6 million)

PPD limited partner equity investment in Celtic Therapeutics Holdings, L.P., an investment partnership organized for the purpose of identifying, acquiring and investing in novel therapeutic products.

PPD disposes of substantially all of the assets of Piedmont Research Center, LLC, a PPD company that performed preclinical research and evaluation of anticancer agents and therapies ($46 million)

PPD equity acquisition of Magen Biosciences, Inc., a biotechnology company focused on the development of dermatologic therapies ($14.9 million)

PPD equity acquisition of AbC.R.O., Inc., a contract research organization operating in Bulgaria, Romania, Serbia, Croatia, Poland, Russia and Ukraine ($40 million)

PRA Health Science equity acquisition of Symphony Health Solutions, Inc., a provider of data and analytics to help professionals understand the full market life cycle of drug products offered for sale by companies in the biopharmaceutical industry ($686.7 million)

PPD equity acquisition of InnoPharm, a contract research organization with assets and operations in Russia and Ukraine ($10 million)

PPD strategic collaboration with Merck & Co., Inc. involving vaccine testing and assay development. Collaboration included PPD’s acquisition of Merck’s 130,000 square foot vaccine testing laboratory and related equipment ($25.2 million)

PPD acquires substantially all of the assets of SurroMed, Inc.’s biomarker business ($35 million)

PPD equity acquisition of Eminent Research Systems, Inc. and Clinsights, Inc., clinical research organizations specializing in medical device development and post-marketing services to medical device and related pharmaceutical companies. ($25 million)

Community Engagement

• Board of Directors, Country Club of Landfall, Wilmington, NC – 2020 to Present
• Finance Committee, Country Club of Landfall, Wilmington, NC  – 2018 to Present
• Governance Committee, Country Club of Landfall, Wilmington, NC  – 2020 to Present
• Rules and Members, Country Club of Landfall, Wilmington, NC  – 2020 to Present
• Greens Committee, Country Club of Landfall, Wilmington, NC – 2020 to Present